Novartis India Ltd Share Price Today, Live NSE/BSE Updates

NSEBSE

There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.

Max

Open925.7

High925.7

Low916.6

Prev. Close918.15

Avg. Traded Price919.91

Volume2,041

MARKET DEPTH

Total bid0.00

Total ask0.00

Orders	Qty	Bid
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

Ask	Qty	Orders
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

HIGH/LOW

52w

LOW/HIGH

₹916.6015 hours ago

₹925.7015 hours ago

LOWER/UPPER CIRCUITS

₹734.55

₹1,101.75

Novartis India Ltd Stock performance

KEY OBSERVATIONS

positive

negative

neutral

Annual Revenue,rose 0.37%, in the last year to ₹398.23 Cr. Its sector's average revenue growth for the last fiscal year was 10.53%.

Annual Net Profit,rose 18.44% in the last year to ₹100.9 Cr. Its sector's average net profit growth for the last fiscal year was 36.7%.

Price to Earning Ratio,is 22.06, lower than its sector PE ratio of 41.8.

LONG-TERM PRICE ANALYSIS

Stock return5Y CAGR : %

Net profit growth 5Y CAGR : 10.47%

Novartis India Ltd Top mutual funds holding

Motilal Oswal BSE Healthcare ETF

3Y Return+24.9%

NAV₹45.34

Motilal Oswal BSE 1000 Index Fund-Reg(G)

3Y Return+0%

NAV₹9.95

Similar stocks

ADANIENT₹2,392.00-6.80 (0.28%)

AEGISLOG₹702.25-12.60 (1.76%)

REDINGTON₹243.80+1.69 (0.70%)

CPPLUS₹1,435.00+36.60 (2.62%)

CELLO₹623.70-2.70 (0.43%)

Novartis India Limited is a pharmaceutical company. The business operations of the Company include Pharmaceuticals Generic over the counter (OTC) and Animal Health. The Pharmaceuticals segment consists of a portfolio of prescription medicines which are provided to patients through healthcare professionals. The Generics segment consists of retail generics products. The Generics segment’s unit primarily focuses on the therapeutic segments such as Anti-TB Anti-DUB (Gynaecology) Anti-histamines Antibiotics Anti-ulcerants Anti-diabetes and Cardiovascular. The Animal Health segment has a presence primarily in the cattle and poultry market segments. The OT C segment is mainly in the vitamins minerals and nutritional supplements (VMS) and cough cold and allergy (CoCoA) market segments. During the fiscal year ended March 31 2012 it introduced Enplus product in the Poultry segment and Dexbov Antifur Vayuhara Vetimam and Feedavit in the Cattle segment..The company also in the business activities of OTC Generics Animal Health Pharmaceuticals.

Grow your wealth with more research recommendations

+91

To visit the old Ventura website, click here.

Ventura Wealth Clients Login here